Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03099161 · ClinicalTrials.gov registry record · Phase 1
Study of Preladenant (MK-3814) Alone and With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3814A-062)
A Phase 1 study, sponsored by Merck Sharp & Dohme.
- Terminated
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT03099161 is a Phase 1 study that was terminated before completion, run by Merck Sharp & Dohme. The registered enrollment target is 10 participants.
The verdict
NCT03099161, a Phase 1 study, was terminated before completion, sponsored by Merck Sharp & Dohme.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and preliminary efficacy of preladenant (MK-3814A) alone and in combination with pembrolizumab (MK-3475) (pembro) in participants with advanced solid tumors that have not responded to prior therapy. This study will be done in 2 parts. Part 1 will identify and confirm the recommended Phase 2 dose (RP2D) of preladenant when given alone or in combination with pembrolizumab. Part 2 of the study will determine the safety and efficacy of preladenant in combination with pembrolizumab at the RP2D in participants with select solid tumors .
Interventions
- BIOLOGICAL pembrolizumab
- DRUG preladenant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2017-06-27 |
| Est. Completion | 2018-02-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03099161
The ClinicalTrials.gov registry entry for NCT03099161 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which pembrolizumab is the first listed.
NCT03099161 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03099161 about?
NCT03099161 is a clinical study titled "Study of Preladenant (MK-3814) Alone and With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3814A-062)". The purpose of this study is to evaluate the safety and preliminary efficacy of preladenant (MK-3814A) alone and in combination with pembrolizumab (MK-3475) (pembro) in participants with advanced solid tumors that have not responded to prior therapy. This study will be done in 2 parts. Part 1 will i...
What is the current status of trial NCT03099161?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2017-06-27. Estimated completion is 2018-02-21.
What interventions are being tested in trial NCT03099161?
The interventions under investigation include: pembrolizumab (BIOLOGICAL), preladenant (DRUG).
Who is sponsoring clinical trial NCT03099161?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.